AbbVie announced on June 22 that it will acquire Apogee Therapeutics for $10.9 billion in cash, adding zumilokibart, an investigational eczema treatment, to an immunology franchise already anchored by Skyrizi and Rinvoq. The price tag is large enough to make income investors ask the obvious question: does a $10.9 billion outflow threaten a dividend streak that stretches back half a century? The short answer, supported by the company's own precedent, is that it does not.
AbbVie enters the deal as a Dividend King, a designation that requires 50 consecutive years of annual increases once its years under Abbott Laboratories are counted. Management treats that streak as existential; a single missed increase resets the clock to zero and forces the company to wait another five decades to reclaim the title. That incentive structure matters more than any single acquisition. AbbVie ended 2025 with $17.8 billion in free cash flow, and the Apogee purchase will be funded with debt, leaving the cash balance intact.
The template is the Allergan acquisition, the largest in AbbVie's history and one of the biggest in pharmaceutical history. That $63 billion mix of cash and stock closed in May 2020. Since then, the dividend has grown 46.6 percent. The Allergan portfolio, Botox, Vraylar, and others, helped AbbVie navigate Humira's patent cliff. The Apogee bet is smaller, cleaner, and explicitly debt-financed.
Skeptics argue that any leverage increase narrows the margin for error. That is true in the abstract, but the source of funding changes the calculus. Debt service is a fixed claim; a dividend cut is a discretionary choice. AbbVie has signaled repeatedly that the latter is not on the table. Meanwhile, zumilokibart could replicate the revenue diversification that Allergan's assets provided, assuming the eczema data hold up.
The near-term story remains Skyrizi and Rinvoq, which continue to carry the top line. The pipeline now includes weight-loss candidates alongside the Apogee asset. If zumilokibart delivers, the deal looks like a disciplined tuck-in at a reasonable multiple. If it fails, the debt remains, but the dividend machine, fed by $17.8 billion of annual free cash flow, keeps running. The market's job is to price the optionality; the company's job is to protect the streak. So far, the two have aligned.